Swiss pharmaceutical giant Roche has fully frozen all future investment decisions in Germany over the country’s healthcare cost-cutting policies, according to Daniel Steiners, who heads the company’s German pharmaceutical business, in an interview with a local newspaper — further escalating tensions between the drug industry and the German government.

“We are putting all future investment decisions in Germany on hold for now,” Steiners said, noting that policymakers had badly damaged industry trust with recent regulatory tightening. He criticized the government for tilting toward short-term cost cutting rather than addressing structural problems in the statutory health insurance system, saying the burden on companies that conduct research, development and manufacturing is growing.

At issue is legislation that would raise the statutory manufacturer rebate on patent-protected medicines to 15.5% from the current 7% starting in January 2027. Germany’s Federal Ministry of Health estimates the measure would save health insurers about €12 billion (approximately $13.5 billion) by 2030, helping to close a funding gap projected at roughly €19 billion (approximately $21.3 billion). Steiners warned that short-term austerity masks structural financing problems and risks driving research and production operations abroad.

He also dismissed the location clauses Berlin has proposed, saying they would only partially ease the rebate burden for companies that do substantial research and manufacturing in Germany and could offset only part of the damage from the legislative change. What is needed is a comprehensive industrial strategy, he stressed, and piecemeal adjustments such as a partial easing of the manufacturer rebate are insufficient. Steiners also said the gap in business conditions is widening between the United States, which actively courts life-sciences capital with subsidies and infrastructure support, and Germany, which is tightening regulation.

A spokesperson for the German Federal Ministry of Health said, “We regret a company’s decision not to base its business in Germany,” adding that it “shows that we and the European Union must take these issues seriously.” The spokesperson said the ministry would advocate stable and attractive framework conditions for the pharmaceutical industry, including negotiations at the European level. Statutory health insurers, meanwhile, defended the government’s reforms. Stefanie Stoff-Ahnis, deputy chair of the GKV umbrella association, argued that drugmakers still enjoy fat profits in Germany and warned that higher drug prices would destabilize the newly balanced insurance finances without delivering concrete benefits to patients.

Roche employs about 18,600 people in Germany and has invested about €3.8 billion (approximately $4.3 billion) since 2020 to expand its domestic sites. Company representatives told a British newspaper that the freeze applies only to unapproved future plans and that construction at its Penzberg biotechnology site and current staffing levels will be maintained for now.

The decision is a blow to the government of Friedrich Merz, which has been pitching Germany as an investment destination. Beyond Roche, U.S. pharmaceutical giant Eli Lilly (LLY) halved a planned €2.3 billion (approximately $2.6 billion) investment in June, Pfizer (PFE) has begun reviewing its German allocations, and Boehringer Ingelheim withdrew a €900 million (approximately $1.0 billion) spending plan. The wave of investment cutbacks by major drugmakers could weigh on Germany’s drug-discovery ecosystem and employment.

On the same day, Roche announced a second partnership with China’s Hansoh Pharmaceutical in the antibody-drug conjugate (ADC) field. Under the agreement, Hansoh will receive a $400 million upfront payment and $110 million on the first anniversary of the deal, plus the right to milestone payments of more than $15 billion. The move highlights Roche’s prioritization of expansion in the Chinese market even as investment decisions in Europe stall.

ItemDetailsScope of freezeFuture unapproved investment plans in GermanyContested legislationRaise manufacturer rebate to 15.5% from 7% in January 2027German government estimateAbout €12 billion (approximately $13.5 billion) in savings by 2030Funding shortfallAbout €19 billion (approximately $21.3 billion)Roche’s German workforceAbout 18,600German investment since 2020About €3.8 billion (approximately $4.3 billion)

Note: Dollar conversions use the figures provided in the source material.

Germany has proposed legislation capping the surge in statutory health insurance costs, and the pharmaceutical industry is pushing back harder, saying the country’s appeal as a research and development hub is being eroded. Roche’s investment freeze stands as a case showing that drug-pricing policy directly affects where companies choose to locate, and is likely to influence debates over healthcare financing reform in other European countries as well.